Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

96.61 -0.05 (-0.05%)

Streaming Delayed Price Updated: 12:52 PM EDT, Mar 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Why Protagonist Therapeutics Shares Are Trading Higher Today ↗

March 07, 2023

Via Benzinga

Top 5 Health Care Stocks That May Collapse In February ↗

February 13, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Protagonist Therapeutics Earnings Perspective: Return On Capital Employed ↗

August 25, 2022

Protagonist Therapeutics (NASDAQ:PTGX) brought in sales totaling $859 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 96.07%, resulting in a loss of $41.04...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 05, 2022

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million.

Via Benzinga

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shareholder Alert: Investigation over Possible Wrongdoing ↗

June 27, 2022

San Diego, CA -- (SBWIRE) -- 06/27/2022 -- Certain directors of Protagonist Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.

Via SBWire

Stocks That Hit 52-Week Lows On Tuesday ↗

April 26, 2022

During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.

Via Benzinga

Why Protagonist Therapeutics Shares Are Crashing Today ↗

April 26, 2022

Via Benzinga

3 Biotech Stocks to Buy Before They Boom ↗

June 01, 2022

It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.

Via InvestorPlace

The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures ↗

May 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More ↗

May 22, 2022

Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.

Via Benzinga

7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years ↗

May 11, 2022

Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.

Via InvestorPlace

Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

April 29, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Regulatory Compliance

Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

April 29, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Regulatory Compliance

Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Protagonist Therapeutics Shares Plummet ↗

April 26, 2022

U.S. stocks remained lower toward the end of trading, with the Dow Jones tumbling more than 500 points on Tuesday.

Via Benzinga

71 Biggest Movers From Yesterday ↗

April 27, 2022

Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 26, 2022

Via Benzinga

Stocks Flounder As Wall Street Rotates Out Of Tech ↗

April 26, 2022

Big Tech stocks are struggling ahead of several key earnings reports.

Via Talk Markets

Mid-Day Market Update: Nasdaq Down 400 Points; Arch Resources Shares Jump ↗

April 26, 2022

U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping 400 points on Tuesday.

Via Benzinga

34 Stocks Moving In Tuesday's Mid-Day Session ↗

April 26, 2022

Gainers Avadel Pharmaceuticals plc. (NASDAQ: AVDL) shares gained 36.3% to $5.74. Shares closed down 36% on Monday, seemingly on no news. Avadel issued a press release Tuesday...

Via Benzinga

The Daily Biotech Pulse - Tuesday, April,26 ↗

April 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Talk Markets

Futures Slide Ahead Of Tech Earnings Deluge ↗

April 26, 2022

Markets in general are preoccupied by the prospect of tighter monetary policy conditions from global central banks to stem rising prices.

Via Talk Markets

Mid-Morning Market Update: Markets Open Lower; Dow Dips 300 Points ↗

April 26, 2022

U.S. stocks traded lower this morning, with the Dow Jones dropping around 300 points on Tuesday.

Via Benzinga

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy ↗

April 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 26, 2022

Via Benzinga

18 Stocks Moving in Tuesday's Pre-Market Session ↗

April 26, 2022

Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:...

Via Benzinga

Protagonist Therapeutics Topline Data from Phase 2 IDEAL Study of PN-943 (450 mg BID) Miss Primary Endpoint ↗

April 25, 2022

Protagonist Therapeutics (NASDAQ: PTGX) announced top-line results from the Phase 2 IDEAL clinical study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).

Via Benzinga

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

April 21, 2022

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm

April 20, 2022

From The Schall Law Firm

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 20, 2022

Gainers

Via Benzinga

EQUITY ALERT: Rosen Law Firm Encourages Protagonist Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – PTGX

April 20, 2022

From The Rosen Law Firm, P.A.

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

All News about Protagonist Therapeutics, Inc. - Common Stock